KEY INDUSTRY DEALS
Ginkgo, hunting for biotech platforms that ‘collect dust,’ scoops up AAV gene therapy capsid specialist (April 5, 2023) | By Annalee Armstrong. Ginkgo Bioworks doesn’t want the biotech industry’s therapies. But it does want the platforms that create them, which is why the cell programming company is buying up StrideBio for its gene therapy intellectual
Continue ReadingCovant Therapeutics Debuts with Boehringer Partnership Targeting ADAR1 (March 29, 2023) | By Ana Mulero. Boston-based Covant Therapeutics gained $10 million upfront in a deal with Boehringer Ingelheim to chase after a cancer immunotherapy target, ADAR1 (adenosine deaminase acting on RNA). The goal is to turn cold tumors hot.
Continue ReadingBicycle, Novartis Ink Oncology Deal Worth up to $1.7B (March 28, 2023) | By Rosemary Scott. Bicycle Therapeutics and Novartis announced Tuesday they have inked a deal worth up to $1.7 billion to discover and develop several targeted radioligand therapies in oncology. The pair will use Bicycle’s proprietary bicyclic peptide (Bicycle) technology to develop what it calls Bicycle radio-conjugates (BRCs)
Continue ReadingWith CTLA-4 Antibody Deal, BioNTech Comes Face-to-Face with BMS’ Yervoy (March 21, 2023) | By Tristan Manalac. Monday, BioNTech inked an exclusive worldwide license and collaboration agreement with Maryland-based biopharma OncoC4 to develop and commercialize its investigational anti-CTLA-4 antibody ONC-392 for solid tumors. The partnership represents BioNTech’s return to its oncology roots. Though BioNTech is
Continue ReadingCHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs Collaboration will leverage CHARM’s DragonFold deep learning platform to identify compounds against targets of interest (March 20, 2023) | By BUSINESS WIRE. LONDON–(BUSINESS WIRE) — CHARM Therapeutics (“CHARM”), a 3D deep learning biotechnology company discovering and developing transformational
Continue ReadingPfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline Pfizer Inc. is set to acquire Seagen Inc. for $229 in cash per Seagen share for a total enterprise value of $43 billion. (March 15, 2023) | By JIM CORNALL. Seagen is a global biotechnology company that discovers, develops, and commercializes cancer medicines. The boards of
Continue ReadingMaaT Pharma Completes a Capital Increase of approximately €12.7 Million with the Support of Current Shareholders-Seventure etc (February 17, 2023) | By Maat Pharma SA. MaaT Pharma Completes a Capital Increase of approximately €12.7 Million with the Support of Current Shareholders Lyon, France, February 17, 2023, 7:30 am CET – MaaT Pharma (EURONEXT: MAAT –
Continue ReadingMerck hands Swedish biotech €10M cash to develop anti-inflammatory drugs (February 16, 2023) | By Katherine Lewin, News Reporter. Merck is betting on Aqilion’s work on a small molecule inhibitor for autoimmune and inflammatory diseases, including neurological diseases. Merck is paying €10 million upfront cash to the Swedish-based biotech in a licensing deal and research collaboration
Continue ReadingAtomic AI Launches with $35 Million Series A Financing to Advance AI-driven RNA Structure Platform for Treating Undruggable Diseases (January 25, 2023) | By BUSINESS WIRE. SAN FRANCISCO — (BUSINESS WIRE) — Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, launched today with a $35
Continue ReadingBIOHM Raises $7.5 Million to Accelerate Microbiome Research, Artificial Intelligence Capabilities and Product Development (January 12, 2023) | By BIOHM Health. The funding round, led by Middleland Capital’s VTC Ventures, will fast-track growth of A.I. technology and targeted, data-driven microbiome formulations CLEVELAND, Jan. 12, 2023 /PRNewswire/ — BIOHM, a leading microbiome company guided by the
Continue Reading